Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Coloplast A/S
  6. News
  7. Summary
    COLO B   DK0060448595

COLOPLAST A/S

(COLO B)
  Report
Delayed Quote. Delayed Nasdaq Copenhagen - 12/03 10:59:46 am
1053.5 DKK   -1.22%
12/03COLOPLAST A/S : Ex-dividend day for final dividend
FA
12/02COLOPLAST A/S : Voting results
PU
12/02Coloplast A/S - Announcement no. 11/2021 - Decisions at the Annual General Meeting 2021
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coloplast A/S : - Announcement no. 04/2021 – Interim Financial Report, 9M 2020/21

08/18/2021 | 06:01am EST

9M 2020/21
Interim financial results, 9M 2020/21
1 October 2020 - 30 June 2021


Coloplast delivered Q3 organic growth of 11% and 33% EBIT margin. Financial guidance narrowed

  • Coloplast delivered 11% organic growth in Q3. Reported revenue in DKK was up by 9% to DKK 4,835 million. Organic growth rates by business area in Q3: Ostomy Care 4%, Continence Care 5%, Interventional Urology 82% and Wound & Skin Care 17%.
  • The Chronic Care business was positively impacted by improving underlying growth in Europe as well as a lower baseline. Growth was partly offset by lower growth in new patients in the US due to COVID-19, in especially Continence Care, as well as distributor destocking due to a prolonged period of lower growth in new patients. Ostomy Care delivered a softer quarter in Emerging markets due to tender phasing in the Middle East and Russia. The tenders are confirmed for delivery in Q4.
  • During Q3, hospital activity increased as vaccines were rolled out and as a result growth in new patients within Ostomy Care normalised towards pre-COVID levels across markets. Growth in new patients within Continence Care is taking longer to normalise as expected, but the trend during Q3 was positive across markets.
  • The Interventional Urology business delivered a strong quarter driven by broad-based recovery in elective procedures led by the US and Men’s Health, as well as a lower baseline.
  • The Wound and Skin Care business delivered a solid quarter. Wound Care alone delivered 20% organic growth driven by Europe and China and strong contribution from the Biatain Silicone portfolio, as well as a lower baseline.
  • EBIT was DKK 1,592 million, a DKK 224 million (16%) increase from last year, corresponding to an EBIT margin of 33% which reflects efficiency gains and lower costs due to COVID-19, partly offset by continued commercial investments.
  • Diluted earnings per share (EPS) increased by 26% to DKK 5.88.

9M organic growth of 6% and 33% EBIT margin

  • Coloplast delivered 6% organic growth year to date. Reported revenue in DKK was up by 3% to DKK 14,326 million. Organic growth rates by business area year to date: Ostomy Care 5%, Continence Care 4%, Interventional Urology 22% and Wound & Skin Care 6%.
  • EBIT before special items amounted to DKK 4,705 million, a 7% increase from last year, corresponding to an EBIT margin before special items of 33% against 31% last year.
  • ROIC after tax before special items was 43% against 45% last year, negatively impacted by last year’s acquisition of Nine Continents Medical. Diluted earnings per share (EPS) before special items increased by 17% to DKK 17.24.

2020/21 financial guidance narrowed – organic growth expected in the lower end of the 7-8% range and EBIT margin expected to be in the upper end of the 32-33% range before special items

  • We now expect organic revenue growth in the lower end of the 7-8% range at constant exchange rates. Reported growth in DKK is still expected to be 4-5%.
  • Reported EBIT margin before special items is now expected to be in the upper end of the 32-33% range. After special items, the reported EBIT margin is now expected to be in the upper end of the 31-32% range.
  • Capital expenditure continues to be expected ~DKK 1.1 billion. The effective tax rate is still expected to be ~23%.

Conference call

Coloplast will host a conference call on Wednesday, 18 August 2021 at 15.00 CEST. The call is expected to last about one hour. To actively participate in the Q&A session please call +45 3544 5577, +44 3333 000 804 or +1 631 913 1422. The participant PIN code is 87004267#. Any participants who do not wish to actively participate in the Q&A session can access the conference call as a webcast directly here: https://getvisualtv.net/stream/?coloplast-x9e5dfwgrq.



For further information, please contact

Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111

Ellen Bjurgert
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 3376
Email: dkebj@coloplast.com

Aleksandra Dimovska
Sr. Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com                                                                                     

Press and the media
Peter Mønster
Sr. Media Relations Manager
Tel. +45 4911 2623
Email: dkpete@coloplast.com 

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com


This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-08.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

  • 04_2021_9M_202021_Earnings_Release

© OMX, source GlobeNewswire - EU Press Releases

All news about COLOPLAST A/S
12/03COLOPLAST A/S : Ex-dividend day for final dividend
FA
12/02COLOPLAST A/S : Voting results
PU
12/02Coloplast A/S - Announcement no. 11/2021 - Decisions at the Annual General Meeting 2021
AQ
12/02Coloplast A/S Elects Annette Br?ls as Member of the Board of Directors
CI
11/09Coloplast A/S - Announcement no. 10/2021 - Notice of Annual General Meeting
AQ
11/08GLOBAL MARKETS LIVE : Qiagen, Alcon, Boeing, Berkshire Hathaway...
11/08Coloplast to acquire Atos Medical in $2.5 billion deal, shares rise
RE
11/08Coloplast A/S - Announcement no. 09/2021 - Coloplast announces agreement to acquire Ato..
AQ
11/08COLOPLAST A/S (CPSE : COLO B) signed an agreement to acquire Atos Medical AB from PAI Euro..
CI
11/01Coloplast A/S Reports Earnings Results for the Full Year Ended September 30, 2021
CI
More news
Analyst Recommendations on COLOPLAST A/S
More recommendations
Financials
Sales 2022 21 205 M 3 227 M 3 227 M
Net income 2022 5 109 M 778 M 778 M
Net Debt 2022 2 051 M 312 M 312 M
P/E ratio 2022 43,8x
Yield 2022 1,84%
Capitalization 224 B 34 057 M 34 121 M
EV / Sales 2022 10,7x
EV / Sales 2023 9,80x
Nbr of Employees 12 728
Free-Float 57,4%
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | COLO B | DK0060448595 | MarketScreener
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 1 053,50 DKK
Average target price 1 075,81 DKK
Spread / Average Target 2,12%
EPS Revisions
Managers and Directors
Kristian Villumsen President & Chief Executive Officer
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Oliver Johansen Senior VP-Global Research & Development
Allan Rasmussen Executive Vice President-Global Operations